Month: December 2019

Illumina, Inc. ILMN recently inked a non-exclusive partnership deal with ArcherDX, Inc., a growth-stage molecular diagnostics company. Both companies aim at developing in-vitro diagnostic (IVD) tests for ArcherDX's portfolio of next-generation sequencing (NGS)-based companion diagnostics […]

On Dec 3, we issued an updated research report on NuVasive, Inc. NUVA . The company continues to witness strength in the global business […]

Petroleo Brasileiro S.A. aka Petrobras PBR aims to become the best value-generating energy company by executing its strategy to boost growth of its business and maximize returns to its shareholders over the next five-year period. To this end, the company has plans in place for achieving the target. […]

It has been a pretty uneventful week for the biotech sector with updates from a few companies. While Incyte INCY got Priority Review for the cholangiocarcinoma drug, Biogen BIIB came out with positive results on the lupus drug. Meanwhile, Seattle Genetics SGEN collaborated with Merck MRK for a combination study […]

The Ensign Group, Inc. ENSG has acquired four skilled nursing facilities in Dallas, TX. Effective Dec 1, 2019, the purchases will be subject to long-term, triple net leases with purchase options following year five of the lease […]

Bristol-Myers Squibb Company BMY and Acceleron Pharma Inc. XLRN announced that the FDA’s Oncologic Drugs Advisory Committee will hold a review of their supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt) in patients with myelodysplastic syndromes (MDS) at the meeting on Dec 18. Bristol-Myers Squibb is seeking approval of Reblozyl for the treatment of adult patients with very low- to intermediate-risk MDS-associated anemia, who have ring sideroblasts and require red blood cell (RBC) transfusions […]

AstraZeneca PLC AZN announced an agreement to sell rights to Seroquel and Seroquel XR, its drugs for the treatment of schizophrenia and bipolar disease, in the United States and Canada to German pharmaceutical company Cheplapharm Arzneimittel GmbH. We remind investors that earlier in October, AstraZeneca sold rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm. The transactions are part of the company’s efforts to focus on reducing the number of mature medicines for enabling reinvestment in the main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. […]

Biogen Inc. BIIB announced positive top-line data from a phase II study evaluating the safety and efficacy of its fully humanized IgG1 monoclonal antibody (mAb) BIIB059. The LILAC study, which evaluated BIIB059 in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), met its primary endpoints by demonstrating statistically significant reduction of disease activity in patients with CLE and SLE, who received BIIB059 compared to placebo […]

salesforce.com Inc. CRM delivered third-quarter fiscal 2020 non-GAAP earnings of 75 cents per share, beating the Zacks Consensus Estimate by 13.64% and also the year-ago quarterly figure by 23%. Meanwhile, revenues of $4.51 billion surged 33% year over year and also surpassed the Zacks Consensus Estimate of $4.436 billion […]

In the past week, Latin American carrier — Gol Linhas Aereas Inteligentes GOL — introduced a new business segment — GOL Aerotech —in Brazil. The division provides aircraft maintenance, repairs, and aircraft and components overhauls (MRO) services to the third parties. […]

President Trump hinted at a delay in the U.S.-China trade agreement until after the 2020 elections on Dec 3, sending jitters across markets. Consequently, the yield on benchmark 10-year Treasury note has plummeted sharply since August. […]

Speaking at the recently held Wells Fargo Global TMT conference, AT&T Inc. ’s T chief financial officer, John Stephens, provided business update to shareholders, shedding more light on the three-year plan initially offered in October along with quarterly results. The telecom and media giant projects consolidated revenues at a CAGR of 1-2% from 2020-2022, and EBITDA margins to grow 200 basis points by 2022 […]

Realty Income Corporation O recently closed the first tranche of the previously-announced transaction with CIM Real Estate Finance Trust, Inc. (“CMFT”) by acquiring 411 properties for $1.035 billion. The transaction marks a major move to boost Realty Income’s portfolio. […]

International Flavors & Fragrances Inc. IFF intends to globally expand the Tastepoint brand through its model across multiple geographic regions for providing localized services to mid-size customers in various locations. The company will enhance its offerings to middle-market customers by leveraging Frutarom’s large client base while also fulfilling specified needs for local markets. […]